| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HEED; COGIS; WAIT1 |
| WB Predicted band size | 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human EED |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于EED抗体的3篇代表性文献，涵盖其功能、应用及疾病关联研究：
---
1. **文献名称**：*Structural Basis of EED Interaction with Histone H3K27me3*
**作者**：Justin P. J. Chong et al.
**摘要**：本研究解析了EED蛋白与组蛋白H3K27三甲基化(H3K27me3)结合的晶体结构，揭示了EED通过其芳香笼结构域特异性识别H3K27me3的分子机制。研究使用EED抗体进行免疫共沉淀实验，验证了EED在PRC2复合体中的表观遗传调控作用，为癌症中EED突变的功能研究提供了结构基础。
---
2. **文献名称**：*EZH2 and EED mutations drive epigenetic dysregulation in pediatric gliomas*
**作者**：Yujie Huang et al.
**摘要**：该研究通过免疫组化(使用EED特异性抗体)和基因组测序，发现儿童胶质瘤中EED和EZH2的突变导致H3K27me3异常分布，进而驱动肿瘤发生。实验表明EED抗体可用于检测肿瘤样本中PRC2复合体的功能状态，为靶向表观遗传治疗的开发提供了依据。
---
3. **文献名称**：*Development of a High-Affinity EED Inhibitor with Anti-Tumor Activity*
**作者**：Qian Chen et al.
**摘要**：研究团队开发了一种新型EED小分子抑制剂，通过阻断EED与H3K27me3的相互作用抑制PRC2活性。文中利用EED抗体进行ChIP-seq和Western blot分析，证实该抑制剂可降低癌细胞中H3K27me3水平并抑制肿瘤生长，为血液系统恶性肿瘤的治疗提供了新策略。
---
**备注**：若需获取具体文献全文或扩展应用场景(如自身免疫疾病、干细胞分化等)，可进一步补充关键词或研究领域进行筛选。
EED (Embryonic Ectoderm Development) is a core component of the Polycomb Repressive Complex 2 (PRC2), an evolutionarily conserved epigenetic regulator. PRC2 catalyzes the trimethylation of histone H3 on lysine 27 (H3K27me3), a post-translational modification associated with transcriptional repression. EED plays a critical role in maintaining PRC2 stability and allosterically activating its methyltransferase activity by binding to H3K27me3. enabling the propagation of this repressive chromatin mark. Dysregulation of EED or PRC2 is linked to developmental disorders, cancers, and other diseases, making EED a key target for studying epigenetic mechanisms.
EED antibodies are essential tools for investigating PRC2 function, enabling the detection, localization, and quantification of EED in various experimental models. They are widely used in techniques like Western blot, immunoprecipitation, and immunofluorescence to explore EED's role in gene silencing, cell differentiation, and tumorigenesis. Specific EED antibodies also aid in studying mutations or dysregulation in cancers, such as lymphomas or gliomas, where PRC2 components are frequently altered. Additionally, they support drug discovery efforts targeting PRC2-EED interactions in epigenetic therapies.
When selecting EED antibodies, factors like species reactivity, application-specific validation, and epitope specificity are crucial to ensure accurate experimental outcomes. Reliable antibodies help unravel EED's structural and functional dynamics, advancing research in epigenetics and disease biology.
×
